SEC Company Response from Vaxart, Inc. (VXRT) (CIK 0000072444) (VXRT) — Jul 13, 2015
Vaxart, Inc. (VXRT) (CIK 0000072444)
Date: July 13, 2015 · CIK: 0000072444 · Accession: 0001437749-15-013520
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-205272
Letter
VIA EDGAR SUBMISSION United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Registration Statement on Form S-3 (File No. 333-205272)
Re: Biota Pharmaceuticals, Inc.
Dear Mr. Riedler:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Biota Pharmaceuticals, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-3 (the “Registration Statement”) be accelerated so the Registration Statement will become effective as of 3:00PM Eastern Time on July 15, 2015, or as soon thereafter as practicable.
The Company hereby acknowledges that:
1. should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
2. the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
3. the Company may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions, or if you require additional information, please do not hesitate to contact me at (212) 698-3616.
Sincerely,
Biota Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm bota20150713_corresp.htm July 13, 2015 VIA EDGAR SUBMISSION Jeffrey P. Riedler Assistant Director United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Biota Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-205272) Dear Mr. Riedler: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Biota Pharmaceuticals, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement on Form S-3 (the “Registration Statement”) be accelerated so the Registration Statement will become effective as of 3:00PM Eastern Time on July 15, 2015, or as soon thereafter as practicable. The Company hereby acknowledges that: 1. should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; 2. the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and 3. the Company may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. If you have any questions, or if you require additional information, please do not hesitate to contact me at (212) 698-3616. Sincerely, Biota Pharmaceuticals, Inc. /s/ Joseph Patti Name: Joseph Patti Title: Chief Executive Officer Cc: David S. Rosenthal, Dechert LLP